Full-Time

Medical Science Liaison – Medical Science Liaison or Senior Medical Science Liaison

Neurology, Alzheimer's Disease

Eisai

Eisai

Pharmaceutical company focused on dementia and oncology

No salary listed

Kansas City, MO, USA

In Person

Residence in Central Midwest (Missouri, Kansas, Nebraska, Iowa); field-based with ~60% travel; home-based office within territory.

PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Requirements
  • Advanced terminal degree in medical or health sciences or related field (MD/DO, PhD, PharmD)
  • 2+ years industry/clinical research/related experience in a scientific or clinical setting
  • Knowledge of treatment guidelines, clinical research processes, FDA regulations, pharma regulations/compliant practices, and OIG guidelines
  • Capable of engaging in frequent business travel (approximately 60% of time)
  • This is a field-based position and requires maintaining a home-based office within defined territory
  • Possession of a valid driver's license and clean driving record
Responsibilities
  • Act as the primary clinical/scientific resource to Health Care Professionals in the territory for information pertaining to disease state and Eisai's product(s) to ensure awareness and understanding
  • Serve as a conduit for accurate and updated clinical, scientific and medical information between Key Opinion Leaders (KOLs)/investigators and the company's Medical Affairs and development groups
  • Establish, foster, cultivate and maintain peer relationships with KOLs in Alzheimer's disease and dementia in which Eisai has current and future interests
  • Present clinical and scientific data on Eisai’s products and relevant therapeutic areas, as requested
  • Support assigned professional congresses in accordance with MSL plan; be prepared to lead congress coverage efforts, including coordination of all MSL activities
  • Identify and report key scientific, clinical and research insights from KOLs to Medical Affairs
  • Maintain and demonstrate thorough and up-to-date knowledge of disease state, study methodology, clinical information, and product data
  • Demonstrate full knowledge of and ability to execute on approved medical platforms/strategies and MSL initiatives
  • Serve as technical/scientific subject matter resource to Eisai cross functional partners
  • Teach, coach and mentor new or less experienced MSLs; assist with supervision/performance evaluation; assume responsibility for special projects
  • Provide valuable contributions to the organization including leadership and strategic planning
  • Facilitate review and follow up of submitted Investigator-Initiated Studies (IISs) and assist with Eisai sponsored trials
  • The MSL may also be involved with providing recommendations for site selection and scientific expertise to Investigators involved in company sponsored studies
Desired Qualifications
  • MSL experience in neurology or complex disease states preferred; prior dementia or Alzheimer’s disease research strongly preferred
  • Established relationships with KOLs in neurology preferred
  • Knowledge of institutions focused on Alzheimer’s disease preferred
  • Clinical trial development and drug launch experience is preferred

Eisai is a Japanese research-based pharmaceutical company that discovers, develops, and markets prescription medicines under its "human health care (hhc)" concept. Its portfolio concentrates on neurology and oncology, including LEQEMBI (lecanemab), an anti-amyloid treatment for Alzheimer's disease now offered in intravenous and subcutaneous forms; lemborexant for insomnia; and the anticancer agent Halaven, developed through worldwide R&D and open-innovation partnerships. The company also runs a global health program that supplies medicines to more than 30 countries, having distributed billions of tablets to help eliminate neglected tropical diseases such as lymphatic filariasis. What sets Eisai apart is this hhc concept, which frames access and affordability—not only innovation—as central to its mission. The goal is to empower people to realize their fullest life by advancing treatments for conditions such as dementia and cancer.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. Leqembi sales rose to JPY 15.4 billion in Q1 FY2026, driving growth.
  • Pfizer and Eisai start Nurtec co-promotion in Japan on September 1, 2026.
  • Eisai’s EMA-validated taletrectinib filing and serplulimab Japan plan expand 2026 revenue options.

What critics are saying

  • Tazverik’s March 19, 2026 Japan discontinuation exposes recurring safety review risk across the oncology portfolio.
  • Leqembi’s China revenue fell to JPY 4.8 billion in Q1 FY2026, showing uneven demand.
  • If Leqembi adoption stalls or ARIA scrutiny tightens, Eisai remains overexposed to one franchise.

What makes Eisai unique

  • Leqembi reached JPY 29.3 billion in Q1 FY2026, validating Eisai’s Alzheimer’s leadership.
  • Hatfield’s £48 million LSIMF-backed expansion internalizes cold-chain packaging for Leqembi and pipeline drugs.
  • Eisai pairs neurology with oncology, licensing taletrectinib and serplulimab during 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Remote Work Options

Home Office Stipend

Phone/Internet Stipend

Company News

EMJ Reviews
Aug 7th, 2026
FDA approves Takeda's first-in-class narcolepsy drug.

FDA approves Takeda's first-in-class narcolepsy drug. Key summary: * FDA clears first drug to treat the underlying cause of narcolepsy type 1. * Takeda forecasts peak annual sales of up to $5bn for Orzeyful. * Rivals including Alkermes, Eli Lilly and Eisai are racing to develop competing therapies. Takeda has secured FDA approval for the first drug to treat the underlying cause of narcolepsy type 1, with the company forecasting peak annual sales of between $2bn and $3bn as it seeks further regulatory approvals. Known as Orzeyful (oveporexton), the therapy is an orexin receptor 2 agonist that restores a brain signal missing in people with narcolepsy type 1. Unlike existing treatments, it targets the underlying cause of the disease rather than simply treating its symptoms. Narcolepsy is a chronic neurological disorder characterised by excessive daytime sleepiness, sudden muscle weakness known as cataplexy, sleep paralysis and vivid hallucinations. For now, Orzeyful is approved only for adults with narcolepsy type 1 in the US. Its safety and efficacy have not yet been established in people younger than 18 years in the country. Orzeyful's efficacy. The approval was backed by positive results from two pivotal clinical trials. In the FirstLight and RadiantLight studies, Orzeyful significantly improved patients' ability to stay awake compared with placebo. The therapy also reduced cataplexy, sleep paralysis, hallucinations and disrupted night-time sleep. The most common adverse events included insomnia, increased urinary frequency, urinary urgency and increased salivation. "The FDA approval of Orzeyful marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and how people feel on treatment," said Julie Kim, President and Chief Executive Officer, Takeda. The company expects to launch Orzeyful in the US in November, subject to scheduling by the Drug Enforcement Administration. Further approvals. The FDA's decision follows Orzeyful's clearance in China last month for adults and adolescents aged 16 years and older. The therapy also remains under review in Japan, while Takeda plans to file for approval in Europe later this year. Although Takeda is first to market, competition is already building. Irish biopharmaceutical company Alkermes is progressing alixorexton through phase 3 trials, while Eli Lilly's cleminorexton and Eisai's ledasorexton are both in phase 2 development. Brain health company Lundbeck is also developing Lu AH69593, which is in phase 1b trials. Press play to listen to this content

FilingReader
Jul 29th, 2026
Eisai reports Leqembi first-quarter global sales.

Eisai reports Leqembi first-quarter global sales. July 29, 2026 at 10:09 AM UTC - By FilingReader AI Eisai announced that global sales revenue for its anti-amyloid beta antibody Leqembi reached 293 billion yen on a pre-audit basis for the first quarter of fiscal year 2026, covering the period from April 1 to June 30, 2026. This figure compares to sales of 231 billion yen in the same period of the previous year. Breaking down the performance by major countries, sales reached 154 billion yen in the United States, 61 billion yen in Japan, and 48 billion yen in China. In the corresponding period of the previous year, regional sales stood at 91 billion yen in the United States, 55 billion yen in Japan, and 77 billion yen in China. This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact [email protected]

Pharma Journalist
Jul 29th, 2026
Pfizer, Eisai partner to co-promote Nurtec in Japan.

Pfizer, Eisai partner to co-promote Nurtec in Japan. On Jul 29, 2026 Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning September 1, 2026. The agreement is designed to expand awareness of the appropriate use of Nurtec among healthcare professionals and improve access to treatment information for patients living with migraine. While both companies will jointly provide medical information to healthcare institutions nationwide, Pfizer will continue to oversee the drug's development, manufacturing, distribution, and commercialization. Nurtec is an oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for both the acute treatment of migraine attacks and the preventive treatment of migraine. The dual indication makes it one of the few oral therapies that can address both immediate symptom relief and long-term prevention. Under the co-promotion arrangement, Pfizer and Eisai will combine their respective strengths to support the broader adoption of Nurtec in clinical practice. Pfizer, as the product's marketing authorization holder, brings its expertise in developing and commercializing innovative medicines, while Eisai contributes its established presence in neurology, one of the company's strategic therapeutic focus areas. The companies said the collaboration is intended to accelerate the delivery of accurate and timely medical information to physicians and healthcare providers. By leveraging their combined healthcare networks, they aim to ensure that patients who may benefit from Nurtec have greater access to appropriate treatment options. Migraine is a chronic neurological disorder that affects millions of people worldwide and is often accompanied by severe headaches, nausea, sensitivity to light, and sensitivity to sound. Frequent migraine attacks can significantly interfere with work, education, family responsibilities, and overall quality of life. Despite advances in treatment, many patients continue to experience inadequate symptom control or remain undiagnosed and undertreated. With migraine placing a substantial burden on both patients and healthcare systems, the companies believe wider awareness of effective treatment options could help improve disease management and patient outcomes. Pfizer and Eisai said the partnership reflects their shared commitment to supporting people living with migraine by promoting the appropriate use of Nurtec. Through the expanded educational and promotional efforts, the companies aim to help more patients receive timely treatment, reduce the impact of migraine attacks, and regain their everyday lives.

Japan Industry News
Jul 27th, 2026
Pfizer and Eisai to co-promote migraine medication in Japan.

Pfizer and Eisai to co-promote migraine medication in Japan. Pfizer Japan Inc. and Eisai Co., Ltd. have announced a collaboration to co-promote the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec(R) OD Tablet 75mg in Japan, beginning September 1, 2026. The medication, known generically as rimegepant sulfate hydrate, is designed for both acute treatment and prophylaxis of migraine. The partnership aims to enhance the dissemination of information regarding the appropriate use of Nurtec in treating migraine, a neurological disorder affecting approximately 8.4% of Japan's adult population. Pfizer will manage the development, manufacturing, distribution, and commercialization of Nurtec, while both companies will provide usage information to medical institutions. Migraine is a prevalent condition characterized by moderate-to-severe headaches and symptoms such as nausea, vomiting, and sensitivity to light and sound. The disorder significantly impacts daily life, with women aged 20-40 being the most affected demographic in Japan. Through this collaboration, Pfizer and Eisai intend to leverage their expertise and healthcare networks to promote the appropriate use of Nurtec, aiming to improve the quality of life for patients suffering from migraines. The initiative underscores the companies' commitment to addressing unmet medical needs and enhancing patient care in the neurology sector.

Packaging World Insights
Jun 22nd, 2026
Eisai advances cold-chain pharma packaging capacity in UK.

Eisai advances cold-chain pharma packaging capacity in UK. Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. - Never miss a story with notifications - Browse free from any location or device. Media Packs Expand Your Reach With Its Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results! - Book a Conference Call